Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 22;11(1):27.
doi: 10.1038/s41537-024-00548-z.

Interpretable machine learning to evaluate relationships between DAO/DAOA (pLG72) protein data and features in clinical assessments, functional outcome, and cognitive function in schizophrenia patients

Affiliations

Interpretable machine learning to evaluate relationships between DAO/DAOA (pLG72) protein data and features in clinical assessments, functional outcome, and cognitive function in schizophrenia patients

Chieh-Hsin Lin et al. Schizophrenia (Heidelb). .

Abstract

Machine learning has been proposed to utilize D-amino acid oxidase (DAO) and DAO activator (DAOA [or pLG72]) protein levels to ascertain disease status in schizophrenia. However, it remains unclear whether machine learning can effectively evaluate clinical features in relation to DAO and DAOA in schizophrenia patients. We employed an interpretable machine learning (IML) framework including linear regression, least absolute shrinkage and selection operator (Lasso) models, and generalized additive models (GAMs) to analyze DAO/DAOA levels using 380 Taiwanese schizophrenia patients. Additionally, we incorporated 27 parameters encompassing demographic variables, clinical assessments, functional outcomes, and cognitive function as features. The IML framework facilitated linear and non-linear relationships between features and DAO/DAOA. DAO levels demonstrated significant associations with the 17-item Hamilton Depression Rating Scale (HAMD17) based on linear regression. The Lasso model identified four features-HAMD17, age, working memory, and overall cognitive function (OCF)-and highlighted HAMD17 as the most significant feature, using DAO from chronically stable patients. Utilizing DAOA from acutely exacerbated patients, the Lasso model also identified four features-OCF, Scale for the Assessment of Negative Symptoms 20-item, quality of life scale (QLS), and category fluency-and emphasized OCF as the most significant feature. Furthermore, GAMs revealed a non-linear relationship between category fluency and DAO in chronically stable patients, as well as between QLS and DAOA in acutely exacerbated patients. The study suggests that an IML framework holds promise for assessing linear and non-linear relationships between DAO/DAOA and various features in clinical assessments, functional outcomes, and cognitive function in patients with schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Category fluency (raw score) and DAO.
Generalized additive models were utilized to examine non-linear relationships between category fluency (raw score) and DAO protein data in the NMDAR pathway in chronic patients (n = 305) with schizophrenia. DAO d-amino acid oxidase, NMDAR N-methyl-d-aspartate receptor. s() is a spline function.
Fig. 2
Fig. 2. Quality of life scale (QLS) and DAOA.
Generalized additive models were utilized to examine non-linear relationships between quality of life scale (QLS) and DAOA protein data in the NMDAR pathway in acutely ill patients (n = 75) with schizophrenia. DAOA d-amino acid oxidase activator, NMDAR N-methyl-d-aspartate receptor. s() is a spline function.

Similar articles

References

    1. Katsanis, S. H., Javitt, G. & Hudson, K. Public health. A case study of personalized medicine. Science320, 53–54 (2008). - PubMed
    1. Snyderman, R. Personalized health care: from theory to practice. Biotechnol. J.7, 973–979 (2012). - PubMed
    1. Lane, H. Y., Tsai, G. E. & Lin, E. Assessing gene-gene interactions in pharmacogenomics. Mol. Diagn. Ther.16, 15–27 (2012). - PubMed
    1. Lin, E. & Chen, P. S. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics9, 935–946 (2008). - PubMed
    1. Lin, E. & Lane, H. Y. Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics16, 555–566 (2015). - PubMed

LinkOut - more resources